Dragana Bubanja

Dragana Bubanja

Auto-generated profile, based on publicly available information

Dragana Bubanja

University of Kragujevac, Faculty of Medical Sciences, Department of Endocrinology, Kragujevac, Serbia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
BPBiljana Parapid
Biljana Parapid
BDBosiljka Djikanovic-Tetikovic
Bosiljka Djikanovic-Tetikovic
Sanja Podunavac-KuzmanovićSanja Podunavac-Kuzmanović
Sanja Podunavac-Kuzmanović
DBDragana Bubanja
Dragana Bubanja
MDMilica Djurovic
Milica Djurovic
VKVladimir Kanjuh
Vladimir Kanjuh
The concept of diversity, equity, inclusion and belonging is essential for research and academic programs and institutions worldwide, but although women do not lag behind men at entry and graduation from Serbian universities, equitable leadership does and it further hinders outcomes in every way: from translational science via healthcare up to legislative efforts to protect children, women and elderly. Although all these may seem as l?art-pour-l?art issues when compared to mere survival in war zones on two continents and all issues women face under circumstances of displacement and bans on rights to education, healthcare and sounds of their own voices in public, still it is the ongoing fight for rights lost in silence and where one least expects it that has to push every human being to fight for the oppressed and underprivileged.

1 December 2023 in AFMN Biomedicine
Verified
Journal Article
Open access
PDF file
TVTijana Veljković
Tijana Veljković
DBDragana Bubanja
Dragana Bubanja
NZNataša Zdravković
Nataša Zdravković
ZTZeljko Todorovic
Zeljko Todorovic
RVRadisa H Vojinovic
Radisa H Vojinovic
MMMladen Maksić
Mladen Maksić
Numerous clinical trials have proven the connection between two glandular organs, in this case, the breast and the thyroid gland. The occurrence of breast cancer (BC) is increased in patients with autoimmune thyroid disease (Hashimoto's thyroiditis and Graves' disease). Patients with Graves' disease have a significantly smaller number of described cases of BC than those with diagnosed Hashimoto's thyroiditis. A 57-year-old female patient came to the emergency center with difficulty breathing. During the examination, ophthalmopathy, weakened breath sound and mastitis of both breasts were found. Hormonal analysis showed the following values: TSH 0.00 (0.3-5.5 mlU/L), FT4 32.90 (11.5-23 pmol/L), TSHRAt 19 (0.0-1.1 U/L), TPOAt 234 (0.0-12 IU/ml), TgAt > 2000 (0.0-30.0 IU/ml). A diagnosis of Graves' disease was established and therapy with thyrosuppressant was started immediately. A multi-detector computed tomography (MDCT) showed a left breast tumor with metastases in the supraclavicular and axillary lymph nodes, infiltration of the tumor into the skin and subcutaneous tissue, as well as metastases in the bones. A biopsy of the breast tumor was performed, and PH findings indicated poorly differentiated ductal carcinoma of the breast, the HER-2+ group of tumors. The early detection of thyroid disease would not lead to the development of a malignant process, and that is why doctors in their clinical work must recognize the first signs of thyroid disease in their patients and immediately start with therapy to reduce the potential risk of BC. There is a significant role in using screening tests to discover breast cancer in patients with untreated or inadequately treated hypo-and hyperthyroidism.